Seres Therapeutics (MCRB) Current Leases (2019 - 2026)

Seres Therapeutics has disclosed Current Leases across 8 years of filings, most recently posting $11.8 million for Q2 2026.

• In Q2 2026, Current Leases rose 24.79% year-over-year to $11.8 million; the TTM figure through Jun 2026 stood at $11.8 million (up 24.79% YoY), while the FY2025 annual figure was $10.4 million, up 19.78% from the prior year.
• Current Leases came in at $11.8 million for Q2 2026 at Seres Therapeutics, up from $10.9 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $11.8 million in Q2 2026 to a low of $3.6 million in Q4 2022.
• Average Current Leases over 5 years is $8.0 million, with a median of $8.5 million recorded in 2024.
• Year-over-year, Current Leases plunged 45.52% in 2022 and jumped 84.64% in 2024.
• Over 5 years, Current Leases stood at $3.6 million in 2022, then jumped by 55.15% to $5.6 million in 2023, then jumped by 55.25% to $8.7 million in 2024, then rose by 19.78% to $10.4 million in 2025, then grew by 13.84% to $11.8 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $11.8 million in Q2 2026, $10.9 million in Q1 2026, and $10.4 million in Q4 2025.